Stories of Technology, Innovation, & Entrepreneurship in the Southeast

Nashville-based Aegis Sciences Corporation, a leading provider of innovative toxicology and healthcare testing solutions, has announced the launch of MedProtectCDM, a groundbreaking tool designed to enhance clinical decision-making by identifying medication nonadherence and potential drug-drug interactions.

This revolutionary oral fluid-based testing solution empowers healthcare providers to optimize treatment strategies for patients receiving treatment for chronic conditions such as hypertension, diabetes, and chronic obstructive pulmonary disease (COPD).

In a news release announcing the new tool, Aegis Sciences Corporation noted that nonadherence to prescribed medications is a significant challenge in chronic disease management, contributing to poor health outcomes and increased healthcare costs. MedProtectCDM bridges this gap by providing clinicians with accurate insights into a patient’s medication use, including prescription and non-prescription substances that may impact treatment efficacy or safety.

The effectiveness of MedProtectCDM is backed by robust scientific research, according to the company. Multiple studies have demonstrated the impact of oral fluid-based medication adherence testing on clinical practice. In the studies performed, Aegis first established characteristics of standard care regarding the identification of medication nonadherence and drug interactions without the availability of a novel tool. After baseline assessment of routine care practices, the company measured differences in clinical performance between those providers with and without access to results from MedProtectCDM.

These studies found significant gaps in care associated with effective identification of nonadherence or drug interactions and highlighted the benefit that a simple, objective assessment such as MedProtectCDM can provide when it is available to clinicians.

---